Diabetes, Obesity & Metabolism最新文献

{"title":"Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m² in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.","authors":"Carel W le Roux, Oren Steen, Kathryn J Lucas, Elena Startseva, Anna Unseld, Samina Ajaz Hussain, Anita M Hennige","doi":"10.1111/dom.16167","DOIUrl":"https://doi.org/10.1111/dom.16167","url":null,"abstract":"<p><strong>Aim: </strong>To explore the effects of sex and baseline body mass index (BMI) on the efficacy and safety of survodutide in people with a BMI ≥27 kg/m².</p><p><strong>Materials and methods: </strong>Totally 387 people (aged 18-75 years, BMI ≥27 kg/m², without diabetes) were randomized 1:1:1:1:1 to once-weekly subcutaneous survodutide (0.6, 2.4, 3.6 or 4.8 mg) or placebo for 46 weeks (20-week dose escalation; 26-week dose maintenance). Participants were categorized according to sex and baseline BMI. Data were analysed descriptively for the full analysis set (FAS), according to dose assigned at randomization (planned treatment) using on-treatment data or all data censored for COVID-19-related treatment discontinuations. (ClinicalTrials.gov number: NCT04667377).</p><p><strong>Results: </strong>After 46 weeks of survodutide treatment, females had greater reductions in bodyweight and waist circumference than males. Participants with a lower baseline BMI had greater proportional reductions in bodyweight than those with a higher baseline BMI; the trend was reversed for reductions in waist circumference. Rates of adverse events (AEs) were comparable between subgroups for sex and baseline BMI. Nausea was the most frequently reported gastrointestinal AE in all subgroups.</p><p><strong>Conclusions: </strong>In people with a BMI ≥27 kg/m², survodutide was associated with clinically meaningful reductions in bodyweight and waist circumference when compared with placebo, in prespecified subgroups based on sex and baseline BMI, and was tolerated at all doses tested.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142996899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of changes in vibration-controlled transient elastography parameters for liver, cardiovascular and mortality outcomes in individuals with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: The Rio de Janeiro type 2 diabetes cohort.","authors":"Nathalie C Leite, Cristiane A Villela-Nogueira, Lorrane V Santos, Claudia R L Cardoso, Gil F Salles","doi":"10.1111/dom.16195","DOIUrl":"https://doi.org/10.1111/dom.16195","url":null,"abstract":"<p><strong>Background/aims: </strong>The prognostic importance of changes in vibration-controlled transient elastography (VCTE) parameters, liver stiffness measurement (LSM), and controlled attenuation parameter (CAP), in individuals with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD) is unknown.</p><p><strong>Methods: </strong>A prospective cohort of 288 patients underwent 2 VCTE exams at least 2 years apart, and the relative percentage changes in LSM and CAP were calculated. Outcomes were the occurrence of any liver-related events (LREs), cardiovascular events (CVEs), and all-cause mortality. Multivariable Cox analyses, adjusted for liver and cardiometabolic factors, assessed associations between VCTE parameters changes, both as continuous and dichotomical variables (LSM increase >15% and CAP reduction >10%), and outcomes.</p><p><strong>Results: </strong>During a median follow-up of 6 years, there were 22 LREs, 28 CVEs, and 37 all-cause deaths. For LREs, baseline LSM was the strongest predictor, but LSM increases added further prognostic value (hazard ratio [HR]: 1.5 [1.0-2.1], 1-SD increment). For CVEs, both LSM increase (HR: 1.7 [1.3-2.3]) and CAP reduction (HR: 1.5 [1.0-2.3], 1-SD decrease) were significant predictors. For all-cause mortality, baseline CAP was a protective predictor. When classified into subgroups based on LSM and CAP changes, the subgroup with both increased LSM and reduced CAP had the highest risks for CVEs (HR:5.3 [1.4-19.6]) and all-cause mortality (HR: 3.4 [1.2-9.6]). The highest risk for LREs was observed in the subgroup with increased LSM without CAP reduction (HR: 3.5 [0.9-12.9]).</p><p><strong>Conclusions: </strong>VCTE parameters changes, LSM increase and CAP reduction, provide prognostic information for adverse liver, cardiovascular, and mortality outcomes in individuals with T2D and MASLD.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142996892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the link between inflammation and brain function after metabolic-bariatric surgery: A year-long fMRI study.","authors":"Magdalena Szwed, Adrian Falkowski, Johanna Seitz-Holland, Alina Borkowska, Maciej Michalik, Marek Kubicki, Krzysztof Szwed","doi":"10.1111/dom.16181","DOIUrl":"https://doi.org/10.1111/dom.16181","url":null,"abstract":"<p><strong>Background: </strong>Metabolic-bariatric surgery (MBS) transcends weight loss and offers wide-ranging health benefits, including positive effects on brain function. However, the mechanisms behind these effects remain unclear, particularly in the context of significant postoperative changes in the inflammatory profile characteristic of MBS. Understanding how inflammation influences postoperative brain function can enhance our decision-making on patient eligibility for MBS and create new opportunities to improve the outcomes of this popular treatment.</p><p><strong>Objective: </strong>To identify brain regions where spontaneous neural activity and functional connectivity are linked with the evolving inflammatory profile following MBS.</p><p><strong>Methods: </strong>We investigated the relationship between the perioperative ratio of interleukin (IL)-6 to IL-10 and both the amplitude of low-frequency fluctuation (ALFF) and functional connectivity across 375 brain regions. We examined 36 patients at three time points: 1 week before, and 3 and 12 months after laparoscopic sleeve gastrectomy.</p><p><strong>Results: </strong>Initially, the IL-6/IL-10 ratio increased during the early postoperative period but then decreased to levels lower than the preoperative values 1 year after surgery. We observed that ALFF in four subcortical structures decreased with a rising IL-6/IL-10 ratio and increased with a declining ratio. Conversely, 16 cortical regions displayed the opposite trend. Additionally, functional connectivity between the left insula and bilateral medial prefrontal cortex increased with a rising IL-6/IL-10 ratio and decreased with a declining ratio.</p><p><strong>Conclusions: </strong>Our study is the first to identify brain regions significantly linked to inflammation after MBS. Importantly, many of the discovered areas were previously shown to be involved in the pathogenesis of obesity or are targets of contemporary medical treatments. Consequently, our findings offer valuable insights for future obesity research, especially in the context of potential therapeutic opportunities.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142996885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apolipoprotein CIII correlates with lipoproteins in the fed state and is not regulated by leptin administration in states of hypoleptinemia induced by acute or chronic energy deficiency: Results from two randomised controlled trials.","authors":"Arantxa Ramirez-Cisneros, Konstantinos Stefanakis, Christos S Mantzoros","doi":"10.1111/dom.16194","DOIUrl":"https://doi.org/10.1111/dom.16194","url":null,"abstract":"<p><strong>Background: </strong>Medications targeting the leptin and Apolipoprotein CIII (APOC3) pathways are currently under development for the treatment of hypertriglyceridaemia. Given that both pathways are implicated in triglyceride regulation, it is unknown whether they function independently or interact under physiological conditions and under acute or long-term energy deficiency.</p><p><strong>Methods: </strong>APOC3 levels and their association with circulating lipids and lipoproteins were evaluated in the context of two randomised controlled studies. In Study-1, 15 healthy individuals were examined under three distinct conditions, each lasting 72 h: isocaloric feeding, fasting with placebo administration and fasting with leptin administered at replacement doses. In Study-2, 20 females with hypoleptinemia due to relative energy deficiency in sport (REDs) for a minimum of 6 months were treated with either leptin or a placebo for 36 weeks.</p><p><strong>Results: </strong>In Study-1, APOC3 levels remained stable across all arms and were unaffected by leptin administration. In the fed state, APOC3 levels presented positive correlations with various VLDL, IDL, LDL and HDL sizes, and free fatty acids (FFA), most of which were not replicated in fasting. During complete energy deprivation, APOC3 was correlated with HDL molecules, glutamine and FFA, whereas its levels were positively associated only with FFA under leptin treatment. In Study-2, APOC3 levels were lower in the leptin group, but this was not a leptin-dependent effect. A positive correlation between APOC3 levels and HDL was observed in the leptin group.</p><p><strong>Conclusions: </strong>These results contribute towards our better understanding of the intricate nature of lipid regulation under energy deficiency, suggesting that medications targeting the leptin and APOC3 pathways act through different metabolic pathways and thus may have independent effects from each other in regulating triglycerides.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142982314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline and cumulative Chinese visceral adiposity index and diabetic kidney disease: A prospective cohort study.","authors":"Ming Sun, Qitong Liu, Yang Liu, Ning Ning, Jin Zhou, Di Zhou, Huancong Zheng, Shouling Wu, Jingli Gao, Yanan Ma","doi":"10.1111/dom.16184","DOIUrl":"https://doi.org/10.1111/dom.16184","url":null,"abstract":"<p><strong>Background: </strong>Diabetic kidney disease (DKD) makes up nearly half of all chronic kidney disease cases and is a major cause of mortality for people with diabetes. However, the study of the association of longitudinal Chinese visceral adiposity index (CVAI) with DKD is still missing.</p><p><strong>Methods: </strong>This prospective cohort study included 7874 diabetes patients from the Kailuan study. These participants had complete repeated waist circumference, body mass index, triglycerides and high-density lipoprotein cholesterol measurements that formed the continuous CVAI records. DKD was defined by increased proteinuria or decreased estimated glomerular filtration rate (eGFR), preceded by diabetes. Cox proportional hazard regression models were used to examine the associations between baseline and cumulative CVAI and the risk of DKD.</p><p><strong>Results: </strong>There is a positive association between the CVAI level, whether baseline or cumulative, and the incidence of DKD among diabetic patients (p for log-rank tests <0.001). Compared to low CVAI level, the high baseline CVAI level was positively associated with the risk of DKD (HR: 1.24, 95% CI: 1.09-1.42), as well as the high cumulative CVAI level (HR: 1.62, 95% CI: 1.29-2.04). In addition, the assumption of linearity for the positive associations between both baseline (P-nonlinear = 0.264, p for overall <0.001) and cumulative (P-nonlinear = 0.765, p for overall <0.001) CVAI with incident DKD was satisfied.</p><p><strong>Conclusions: </strong>Higher baseline and cumulative CVAI are associated with a higher risk of DKD. This finding suggests the health benefits of low levels of CVAI and the importance of its regular surveillance among individuals with diabetes.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142982023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of changes in the type 2 diabetes and MASLD/related SLD status with risk of developing cardiovascular disease.","authors":"Yasuhiro Matsubayashi, Kazuya Fujihara, Laymon Khin, Efrem d'Àvila Ferreira, Shizuka Takabayashi, Yuko Yamashita, Takaho Yamada, Satoru Kodama, Hirohito Sone","doi":"10.1111/dom.16196","DOIUrl":"https://doi.org/10.1111/dom.16196","url":null,"abstract":"<p><strong>Background & aims: </strong>This study assessed the association of remission of type 2 diabetes mellitus (DM) or metabolic dysfunction-associated steatotic liver disease (MASLD)/related SLD (r-SLD; MASLD with excessive alcohol intake) as defined by the fatty liver index with the risk of cardiovascular disease (CVD).</p><p><strong>Methods: </strong>Health examination data at baseline and after 2 years (2-Years) were extracted from a nationwide claims database in Japan. Among participants aged 18-72 years with at least 3 years of follow-up, 9345 participants with DM-associated MASLD/r-SLD and 71 932 participants with non-DM MASLD/r-SLD at baseline were included in the study. The participants were stratified by the achievement of remission of MASLD/r-SLD or DM at 2-Years. In each group after stratification, the risk of new-onset CVD during the observation period was analysed using multivariate Cox proportional hazards models.</p><p><strong>Results: </strong>During a median follow-up of 4.9 years (starting from 2-Years), 1368 cases of CVD were observed. The hazard ratio (95% confidence interval) for CVD was 0.50 (0.31-0.80) for participants with remission of DM, 0.65 (0.47-0.91) for participants with remission of MASLD/r-SLD, and 0.34 (0.15-0.77) for participants with remission of both DM and MASLD/r-SLD. Conversely, remission of MASLD/r-SLD was not linked to a reduced risk of CVD in participants with non-DM MASLD/r-SLD.</p><p><strong>Conclusion: </strong>The association of MASLD/r-SLD remission with CVD risk differs greatly in the presence and absence of DM. In patients with DM-MASLD/r-SLD, MASLD/r-SLD remission can significantly reduce CVD risk similarly as remission of DM.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142982319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: Patient-reported outcomes from the STEP 1–4 trials”","authors":"","doi":"10.1111/dom.16205","DOIUrl":"10.1111/dom.16205","url":null,"abstract":"&lt;p&gt;\u0000 &lt;span&gt;Rubino, D&lt;/span&gt;, &lt;span&gt;Bjorner, JB&lt;/span&gt;, &lt;span&gt;Rathor, N&lt;/span&gt;, &lt;span&gt;Sharma, AM&lt;/span&gt;, &lt;span&gt;Huth, Smith L&lt;/span&gt;, &lt;span&gt;Wharton, S&lt;/span&gt;, &lt;span&gt;Wadden, T&lt;/span&gt;, &lt;span&gt;Zeuthen, N&lt;/span&gt;, &lt;span&gt;Kolotkin, RL&lt;/span&gt;. &lt;span&gt;Diabetes&lt;/span&gt;, &lt;i&gt;Obesity and Metabolism&lt;/i&gt; &lt;span&gt;2024&lt;/span&gt;; &lt;span&gt;26&lt;/span&gt;(&lt;span&gt;7&lt;/span&gt;): &lt;span&gt;2945&lt;/span&gt;–&lt;span&gt;2955&lt;/span&gt;. DOI: 10.1111/dom.15620\u0000 &lt;/p&gt;&lt;p&gt;In the abstract, the p-value for the difference in achievement of the MWPC threshold for SF-36v2 Physical Functioning was reported as &lt;i&gt;p&lt;/i&gt; = 0.00001; the correct value is &lt;i&gt;p&lt;/i&gt; = 0.0005 (as shown in Figure 2).&lt;/p&gt;&lt;p&gt;In Table 1, the SD of the age of participants in STEP 4 was reported as 11.9; the correct value is 11.7. The waist circumference of participants in STEP 1 was reported as 114 cm; the correct value is 114.7 cm. The number and proportion of participants in STEP 1 with prediabetes were reported as 855 and 43.6%; the correct values are 856 and 43.7%.&lt;/p&gt;&lt;p&gt;In section 3.2.2, the proportion of participants receiving placebo in STEP 1 who reached the ≥4.5 point MWPC threshold was reported as 13.0%; the correct value is 12.9%. The ETD for STEP 4 was reported as 5.0; the correct value is 4.9.&lt;/p&gt;&lt;p&gt;In section 3.2.3, the Figure S6 p-values were summarized as &lt;i&gt;p&lt;/i&gt; &lt; 0.001; the correct summary is &lt;i&gt;p&lt;/i&gt; &lt; 0.01.&lt;/p&gt;&lt;p&gt;In Figure 1B, some error bars did not align with the 95% CIs shown in the column on the right. In Figure 1A and 1B, there were some minor rounding errors in a small number of the data points in the columns.&lt;/p&gt;&lt;p&gt;In Figure 2B, the upper 95% CIs for the STEP 1 and STEP 2 SF-36v2 ETDs were reported as 20.9 and 21.3; the correct values are 20.8 and 21.2.&lt;/p&gt;&lt;p&gt;In Table S4, the ETD for proportion of participants achieving MWPC for Psychosocial score for STEP 2 was reported as 5.4; the correct value is 5.3. The upper 95% CI for Physical score for STEP 2 was reported as 11.2; the correct value is 11.3.&lt;/p&gt;&lt;p&gt;In Figure S6B, the number participants in STEP 2 with &lt;5% weight loss was reported as 582; the correct value is 542.&lt;/p&gt;&lt;p&gt;In Figure S7B, the upper 95% CI for the STEP 1 full trial population ETD was reported as 20.9; the correct value is 20.8. The proportion of participants in STEP 2 with poor PF at baseline in the semaglutide group achieving MWPC was reported as 53.6%; the correct value is 53.5%. The proportions of participants in the full trial population achieving this threshold were reported as 18.0% for the semaglutide group and 6.6% for the placebo group; the correct values are 41.0% and 27.3%. The upper 95% CI for the corresponding ETD was reported as 21.3; the correct value is 21.2. The p-value for this ETD was reported as &lt;i&gt;p&lt;/i&gt; = 0.0061; the correct value is &lt;i&gt;p&lt;/i&gt; = 0.0005.&lt;/p&gt;&lt;p&gt;In Figure S9B, the baseline value for ‘Unable to stand comfortably’ was reported as 2.11; the correct value is 2.06. The baseline value for ‘Unable to walk far/quickly’ was reported as 2.57; ","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":"27 3","pages":"1631"},"PeriodicalIF":5.4,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dom.16205","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142977031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of antidiabetic agents on lipid metabolism of skeletal muscle: A narrative review.","authors":"Ming Xu, Dongqing Lv, Hongxia Wei, Zhe Li, Shuqing Jin, Qinhao Liu, Yi Zhang, Yunfeng Liu","doi":"10.1111/dom.16189","DOIUrl":"https://doi.org/10.1111/dom.16189","url":null,"abstract":"<p><p>Metabolic syndrome-related diseases frequently involve disturbances in skeletal muscle lipid metabolism. The accumulation of lipid metabolites, lipid-induced mitochondrial stress in skeletal muscle cells, as well as the inflammation of adjacent adipose tissue, are associated with the development of insulin resistance and metabolic dysfunction. Consequently, when antidiabetic medications are used to treat various chronic conditions related to hyperglycaemia, the impact on skeletal muscle lipid metabolism should not be overlooked. However, current research has predominantly focused on muscle mass rather than skeletal muscle lipid metabolism and its interplay with glucose metabolism. In this review, we summarised the latest research on the effects of antidiabetic drugs and certain natural compounds with antidiabetic activity on skeletal muscle lipid metabolism, focusing on data from preclinical to clinical studies. Given the widespread use of antidiabetic drugs, a better understanding of their effects on skeletal muscle lipid metabolism merits further attention in future research.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142977034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of insulin sensitivity, insulin secretion, and beta cell function on the remission of type 2 diabetes: A post hoc analysis of the IDEATE trial.","authors":"Xianglin Wu, Qiuyue Huang, Yi Ding, Qiuyu Cao, Youjin Jiang, Yu Xu, Zhiyun Zhao, Min Xu, Jieli Lu, Tiange Wang, Guang Ning, Weiqing Wang, Yufang Bi, Yuchen Xu, Mian Li","doi":"10.1111/dom.16180","DOIUrl":"https://doi.org/10.1111/dom.16180","url":null,"abstract":"<p><strong>Aims: </strong>To compare the probability of achieving diabetes remission in individuals with different phenotypes of insulin sensitivity, insulin secretion, and beta cell function and further detect the effects of diet, exercise, and lifestyle education intervention on these indexes.</p><p><strong>Methods: </strong>Three-hundred and one participants who had glycated haemoglobin (HbA1c) data at baseline and after intervention were included for this post hoc analysis. We used the multi-way analysis of variance to assess the differences between the diabetes remission and non-remission groups or between intervention groups in changes of the indexes of insulin sensitivity, insulin secretion, and beta cell function. Furthermore, logistic regression analysis was used to identify the association between the diabetes remission and baseline and change of each insulin index.</p><p><strong>Results: </strong>Participants with a higher disposition index (DI) or higher adaptation index at baseline were more likely to achieve diabetes remission. The diabetes remission group had a significantly greater increase in AUC_c-pep0-30/AUC_gluc0-30, DI, and adaptation index compared with the non-remission group, while there were no between-group differences in indexes of insulin sensitivity. Participants with greater increases in insulin secretion and beta cell function were more likely to achieve diabetes remission. Indexes of beta cell function improved in all intervention groups, while the diet intervention induced significant improvement compared with lifestyle education.</p><p><strong>Conclusions: </strong>These findings supported the importance of aggressively implementing intensive lifestyle interventions for individuals with type 2 diabetes at an early stage of the disease, when beta cell function was not yet significantly impaired, to promote achieving diabetes remission.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142977033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemerin loss-of-function attenuates glucagon-like peptide-1 secretion in exercised obese mice","authors":"Qilong Zhang PhD,&nbsp;Yi Jia PhD,&nbsp;Yifan Guo PhD,&nbsp;Xiaohan Yu PhD,&nbsp;Ru Wang PhD,&nbsp;Xiaohui Wang PhD","doi":"10.1111/dom.16126","DOIUrl":"10.1111/dom.16126","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>To investigate the role of chemerin reduction in mediating exercise-induced Glucagon-like peptide-1 (GLP-1) secretion and the amelioration of pancreatic β-cell function in obesity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Obesity models were established using wild-type and chemerin systemic knockout mice, followed by 8 weeks of moderate-intensity continuous aerobic exercise training. Serum chemerin levels, GLP-1 synthesis, glucose tolerance, pancreatic β-cell function, structure, and apoptosis were assessed. In vitro experiments were conducted on STC-1 cells, derived from murine intestinal endocrine cells, to evaluate GLP-1 secretion following exogenous chemerin treatment. Additionally, colonic tissue inflammation and apoptosis were analyzed using qPCR and TUNEL staining.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In obese wild-type mice, moderate-intensity aerobic exercise significantly reduced serum chemerin levels, enhanced GLP-1 secretion, and improved glucose tolerance, pancreatic β-cell structure, function, and apoptosis. These effects were absent in obese chemerin knockout mice. Exogenous chemerin treatment reduced GLP-1 secretion in STC-1 cells. Furthermore, the beneficial effects of exercise on colonic inflammation and apoptosis observed in wild-type mice were abolished in chemerin knockout mice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Reduction of chemerin is crucial for the beneficial effects of aerobic exercise on GLP-1 secretion and pancreatic β-cell function in obesity. The mechanisms behind these effects may involve improvements in colonic inflammation and apoptosis. These findings offer new insights into the molecular mechanisms through which exercise improves obesity-related metabolic dysfunction.</p>\u0000 </section>\u0000 </div>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":"27 3","pages":"1296-1313"},"PeriodicalIF":5.4,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}